（编辑 任世碧） 证券日报网讯 2月24日，莱美药业在互动平台回答投资者提问时表示，公司子公司四川瀛瑞的纳米炭铁 混悬注射液（CNSI-Fe）联合放疗已正式进入二期临床阶段，四川瀛瑞正积极推进相关工作，确保试验 的顺利进行。关于该产品研发进展情况公司将严格按照相关规定履行信息披露义务。 ...

此外，公司近期公告显示，2025年业绩预告中提及的研发项目（如创新抗癌药物临床试验进展）和产品 管线更新可能持续受到市场关注，但具体未来事件需以官方公告为准。 以上内容基于公开资料整理，不构成投资建议。 经济观察网 莱美药业在2026年值得关注的事件主要是2025年年度报告的披露。根据报道，公司已预约 于2026年3月21日正式披露2025年年度报告，这将提供完整的财务数据和业务进展细节。 业绩经营情况 ...

Group 1 - The company Guangxi Wuzhou Zhongheng Group Co., Ltd. announced that its subsidiary Chongqing Laimei Pharmaceutical Co., Ltd. and its wholly-owned subsidiary Hunan Kangyuan Pharmaceutical Co., Ltd. participated in the national centralized procurement for drugs whose agreements have expired, with some products expected to be selected for procurement [1][2] - The selected products are projected to generate a total sales revenue of 106.19 million yuan in 2024, accounting for 4.68% of the company's total revenue for that year. For the first three quarters of 2025, the expected sales revenue is 66.07 million yuan, representing 3.39% of the company's revenue for that period [1][2] Group 2 - The procurement is organized by a national alliance consisting of various provinces and regions, with Jiangsu, Henan, and Guangdong provinces leading the initiative. The procurement aims to ensure that medical institutions prioritize the selected products, which is expected to enhance sales and market expansion for the company [2]

Core Viewpoint - The news summarizes important announcements from various companies, highlighting significant developments in their operations and financial performance. Company Announcements - Tianfeng Securities received a notice from the China Securities Regulatory Commission regarding a case of information disclosure violation related to Fujian Yong'an Forestry Group, and the company will cooperate with the investigation [3] - Southwest Securities plans to raise no more than 6 billion yuan through a private placement to supplement its capital and optimize its capital structure [4] - Qiaoyin Co. has terminated its investment in the artificial intelligence industry headquarters project due to changes in cooperation conditions, with a planned investment of no more than 1 billion yuan [5] - Zongshen Power is planning a major asset swap with Longxin General, aiming to resolve competition issues and promote clearer business development [6] - Laimei Pharmaceutical's selected products for national centralized procurement are expected to generate 106 million yuan in sales for 2024, accounting for 13.35% of the company's revenue [7] Performance Reports - Huayin Technology reported a net profit of 313 million yuan for 2025, a decrease of 24.28%, with revenue of 1.251 billion yuan, up 9.83% [9] - Youlide announced a net profit of 152 million yuan for 2025, down 16.88%, with revenue of 1.221 billion yuan, up 7.99% [10][11] - Fudan Microelectronics reported a net profit of 232 million yuan for 2025, a decline of 59.42%, with revenue of 3.982 billion yuan, up 10.92% [12] - Hanzhong Precision reported a net profit of 470 million yuan for 2025, down 45.54%, with revenue of 2.928 billion yuan, a decrease of 20.32% [13] Shareholding Changes - Gaomei Co.'s controlling shareholder and several directors plan to reduce their holdings by up to 3.19% of the company's shares [15] - Guanghuan New Network's controlling shareholder intends to reduce its stake by up to 3% [16] - ST Yigou's shareholder plans to reduce its holdings by up to 2.5% [17] - Juguang Technology's shareholders plan to collectively reduce their holdings by up to 2.3339% [18] - Xiandai Jidian's shareholder intends to reduce its stake by up to 2.05% [19] - Zhejing Pharmaceutical's shareholders plan to reduce their holdings by up to 1.0385% [21] Contract Signings - China Nuclear Construction signed contracts worth 3.393 billion yuan in January, with total revenue of 7.69 billion yuan [23] - China Chemical signed contracts totaling 36.925 billion yuan in January, including significant contracts over 500 million yuan [24]

Group 1 - RuiLian New Materials reported a total operating revenue of 1.677 billion yuan for 2025, an increase of 14.95% year-on-year, with a net profit of 311 million yuan, up 23.48% year-on-year [1] - China Shenhua's subsidiary, Guoneng Qingyuan Power, successfully put its fourth generator unit into commercial operation, expected to provide approximately 20 billion kWh of clean energy annually [2] - Qijiang Airlines announced a 6.04% year-on-year decline in passenger turnover for January 2026, with a passenger load factor of 84.03%, up 1.61% year-on-year [3] Group 2 - QiZheng Tibetan Medicine reported a total operating revenue of 2.416 billion yuan for 2025, a year-on-year increase of 3.34%, with a net profit of 646 million yuan, up 10.98% year-on-year [5] - QiaoYin Co. announced the termination of its artificial intelligence industry headquarters project due to changes in investment cooperation conditions [6] - New Point Software plans to use 90.81 million yuan of surplus raised funds for new projects, including AI-driven software development [7] Group 3 - High Measurement Co. announced plans for major shareholders and executives to reduce their holdings by up to 3.19% of the company's shares [8] - SAIC Group's subsidiary plans to establish a private equity fund with an initial scale of 2.5 billion yuan, focusing on solid-state batteries and chip localization [9] - Tianqi Lithium announced the resignation of its deputy general manager due to personal career planning [10] Group 4 - ZhongKong Technology reported a total operating revenue of 8.051 billion yuan for 2025, a decrease of 11.90%, with a net profit of 450 million yuan, down 59.70% year-on-year [11] - Spring Airlines reported a 6.28% year-on-year increase in total passenger volume for January 2026, with a total available ton-kilometers of 57,008.37 [12] - Qifan Cable's controlling shareholder reduced its stake by 3% through various trading methods [13] Group 5 - China Chemical signed contracts worth a total of 36.925 billion yuan in January 2026, with significant contracts exceeding 5 billion yuan totaling 11.371 billion yuan [19] - SaiTuo Bio received a CEP certificate for its raw material drug Betamethasone, which is used to treat allergies and autoimmune inflammation [20] - Giant Star Agriculture reported a sales revenue of 649 million yuan from commodity fat pigs in January 2026, with a sales volume of 404,400 pigs [23] Group 6 - Qinglong Pipe Industry's subsidiary won a 146 million yuan pipeline project [24] - Changshan Pharmaceutical announced that some of its products are expected to be selected for national centralized procurement [26] - Yangdian Technology completed the transfer of 12.96% of its shares through an agreement [27] Group 7 - Deepin Technology's investment fund introduced new limited partners and adjusted the capital contributions of some partners [28] - Qingyun Technology plans to pledge 25% of its shares for a loan application of up to 30 million yuan [29] - LaiMei Pharmaceutical reported a 57.20% year-on-year decline in net profit for 2025 [30] Group 8 - YouLiDe reported a 16.88% year-on-year decline in net profit for 2025, with total operating revenue of 1.221 billion yuan, up 7.99% [31] - Warner Pharmaceutical reported a net profit of 241 million yuan for 2025, an increase of 46.95% year-on-year [32] - LianRui New Materials reported a net profit of 293 million yuan for 2025, an increase of 16.42% year-on-year [33] Group 9 - HuaQin Technology expects a 24.28% year-on-year decrease in net profit for 2025, with projected revenue of 1.251 billion yuan, up 9.83% [34] - QiPai Technology's shareholder subscribed for 6.3 million shares, accounting for 5.49% of the total share capital [35] - Qilin Security's shareholders completed their planned share reductions without exceeding the original plan [36] Group 10 - Dameng Data announced the lifting of the detention of its senior vice president, allowing him to resume his duties [37] - Haiyou Engineering won a contract for the "NFPS COMP5" project worth approximately 4 billion USD, with the company's share exceeding 800 million USD [38] - Yatai Group plans to sell 20.81% of its shares in Northeast Securities, pending confirmation of financial statements [39]

Core Viewpoint - Laimei Pharmaceutical announced participation in the national centralized procurement for drugs whose agreements have expired, with some products expected to be selected in the upcoming procurement process [1] Group 1: Company Announcement - Laimei Pharmaceutical and its wholly-owned subsidiary, Hunan Kangyuan Pharmaceutical Co., Ltd., participated in the bidding organized by the National Centralized Procurement Office for drugs whose agreements have expired [1] - The National Centralized Procurement Office published the proposed selection results on February 10, 2026, indicating that some products from Laimei Pharmaceutical and Hunan Kangyuan are expected to be selected [1]

Core Viewpoint - Lai Mei Pharmaceutical (300006.SZ) and its wholly-owned subsidiary Hunan Kangyuan Pharmaceutical Co., Ltd. participated in the bidding for the continuation procurement organized by the National Organization for Drug Procurement, with some products expected to be selected in the upcoming procurement [1] Group 1 - The company and Hunan Kangyuan recently engaged in the bidding process for the continuation procurement of drugs whose agreements have expired [1] - The National Organization for Drug Procurement announced the proposed selection results on February 10, 2026 [1] - Some products from the company and Hunan Kangyuan are anticipated to be selected in this continuation procurement [1]

Core Viewpoint - The company, along with its wholly-owned subsidiary Hunan Kangyuan Pharmaceutical Co., Ltd., is participating in the procurement bidding for drugs after the expiration of the national organized procurement agreement, with some products expected to be selected for this follow-up procurement [1] Group 1 - The projected sales revenue for the selected products in 2024 is 106 million yuan, accounting for 13.35% of the company's total revenue for that year [1] - For the first three quarters of 2025, the sales revenue is expected to be 66.0742 million yuan, representing 11.37% of the company's revenue during that period [1]

证券代码：300006 证券简称：莱美药业 公告编号：2026-006 重庆莱美药业股份有限公司 | | 氨曲南注射剂 | 治疗敏感革兰氏阴性菌引起的感染。 | | --- | --- | --- | | 湖南康源制药有 | 甲硝唑注射剂型 | 治疗和预防厌氧菌感染。 | | 限公司 | | | 本次接续采购拟中选产品的拟中选价格、拟中选数量及拟供应区域以接续采购 办公室发布的最终数据为准，采购周期为自中选结果执行之日起至 2028 年 12 月 31 日。 二、本次拟中选对公司的影响 上述拟中选产品品种 2024 年度合计销售收入为 10,618.89 万元，占公司 2024 年 度营业收入比例为13.35%（数据已经审计）；2025年前三季度合计销售收入为6,607.42 万元，占公司 2025 年前三季度营业收入比例为 11.37%（数据未经审计）。 本次接续采购由全国各省（自治区、直辖市）和新疆生产建设兵团组成采购联 盟，委托江苏省、河南省和广东省牵头，对原国家组织集采 1-8 批协议期满的品种， 开展全国统一接续采购工作。在采购周期中，医疗机构将优先使用本次接续采购中 选产品，并确保完成约定采购量。 ...

Core Viewpoint - The company, Laimei Pharmaceutical, announced that its wholly-owned subsidiary, Hunan Kangyuan Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the sodium lactate Ringer's injection (specification: 500ml) [2] Group 1 - Laimei Pharmaceutical's subsidiary has been granted a drug supplement application approval notice [2] - The approved product is sodium lactate Ringer's injection, which is a significant addition to the company's product portfolio [2]